i-STAT to go it alone after Abbott deal ends
This article was originally published in Clinica
Diagnostic company i-STAT is to resume direct distribution of its products from January 1 2004, the day after its five-year exclusive pact with Abbott comes to an end. The company is choosing not to continue its distribution deal for its blood analysis products with the larger company and will be obliged to pay Abbott around $70m over several years.
You may also be interested in...
Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.
The US FDA’s decision to ask on device adverse event reports whether the device involved had been serviced by a third party could help the agency as well as device makers, says Ricki Chase, compliance practice director at Lachman Consultant Services.